FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947843536> ?p ?o ?g. }

• W2947843536 endingPage "1055" @default.
• W2947843536 startingPage "1055" @default.
• W2947843536 abstract "1055 Background: The rarity of BC in men limits the feasibility of randomized clinical studies in this population. Treatment guidelines recommend that men with BC be treated similarly to postmenopausal women. PAL, a cyclin-dependent kinase 4/6 inhibitor, is used in men with metastatic BC (mBC) in real-world clinical practice, presenting an opportunity to utilize real-world evidence to enable healthcare providers to assess novel agents in this space. Methods: Two parallel approaches were taken. In the first approach, pharmacy and medical claims data from IQVIA Inc were retrospectively analyzed to describe the treatment patterns and duration of PAL + ET (aromatase inhibitor or fulvestrant) compared to ET in men with mBC. The second approach was a retrospective analysis of data derived from electronic health records in the Flatiron Health database to understand real-world clinical response to PAL + ET vs ET alone. Median duration of treatment (mDOT) was estimated by the Kaplan-Meier method. Results: Between Feb 2015 and Apr 2017, 12.9% (147/1139 [IQVIA dataset]) of men receiving treatment for mBC were prescribed PAL + ET for any line of therapy. The mDOT in the first-line setting was numerically longer in the PAL cohort (n=37) compared with the non-PAL cohort (n=214; 8.5 vs 4.3 mo, respectively). In particular, mDOT in the first-line setting was longer with PAL + letrozole (LET; n=26) than with LET alone (n=63; 9.4 vs 3.0 mo, respectively). In the Flatiron Health dataset between Feb 2015 and July 2017, the real-world maximum response rate in the PAL + ET cohort across all lines of therapy in the mBC setting (n=12) was 33.3% (2 complete responses [CR], 2 partial responses [PR]) vs 12.5% (0 CR, 1 PR) for the ET alone cohort (n=8). Conclusions: The real-world data sources used in this study support that men with mBC derive clinical benefit from the addition of PAL to ET. Given the challenges of conducting randomized clinical trials in men with mBC, noninterventional, real-world evidence data appear to be useful to delineate the benefit of such therapies in this setting. Funding: Pfizer." @default.
• W2947843536 created "2019-06-07" @default.
• W2947843536 creator A5010886287 @default.
• W2947843536 creator A5030004866 @default.
• W2947843536 creator A5038894713 @default.
• W2947843536 creator A5047768231 @default.
• W2947843536 creator A5053907671 @default.
• W2947843536 creator A5054571533 @default.
• W2947843536 creator A5061176953 @default.
• W2947843536 creator A5061648315 @default.
• W2947843536 creator A5063153537 @default.
• W2947843536 creator A5064301551 @default.
• W2947843536 creator A5070106044 @default.
• W2947843536 creator A5072786134 @default.
• W2947843536 creator A5078251366 @default.
• W2947843536 creator A5078768064 @default.
• W2947843536 creator A5082786012 @default.
• W2947843536 date "2019-05-20" @default.
• W2947843536 modified "2023-09-26" @default.
• W2947843536 title "Real-world evidence of male breast cancer (BC) patients treated with palbociclib (PAL) in combination with endocrine therapy (ET)." @default.
• W2947843536 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.1055" @default.
• W2947843536 hasPublicationYear "2019" @default.
• W2947843536 type Work @default.
• W2947843536 sameAs 2947843536 @default.
• W2947843536 citedByCount "10" @default.
• W2947843536 countsByYear W29478435362020 @default.
• W2947843536 countsByYear W29478435362021 @default.
• W2947843536 countsByYear W29478435362022 @default.
• W2947843536 crossrefType "journal-article" @default.
• W2947843536 hasAuthorship W2947843536A5010886287 @default.
• W2947843536 hasAuthorship W2947843536A5030004866 @default.
• W2947843536 hasAuthorship W2947843536A5038894713 @default.
• W2947843536 hasAuthorship W2947843536A5047768231 @default.
• W2947843536 hasAuthorship W2947843536A5053907671 @default.
• W2947843536 hasAuthorship W2947843536A5054571533 @default.
• W2947843536 hasAuthorship W2947843536A5061176953 @default.
• W2947843536 hasAuthorship W2947843536A5061648315 @default.
• W2947843536 hasAuthorship W2947843536A5063153537 @default.
• W2947843536 hasAuthorship W2947843536A5064301551 @default.
• W2947843536 hasAuthorship W2947843536A5070106044 @default.
• W2947843536 hasAuthorship W2947843536A5072786134 @default.
• W2947843536 hasAuthorship W2947843536A5078251366 @default.
• W2947843536 hasAuthorship W2947843536A5078768064 @default.
• W2947843536 hasAuthorship W2947843536A5082786012 @default.
• W2947843536 hasConcept C121608353 @default.
• W2947843536 hasConcept C126322002 @default.
• W2947843536 hasConcept C143998085 @default.
• W2947843536 hasConcept C167135981 @default.
• W2947843536 hasConcept C2775930923 @default.
• W2947843536 hasConcept C2777176818 @default.
• W2947843536 hasConcept C2778812593 @default.
• W2947843536 hasConcept C2779744173 @default.
• W2947843536 hasConcept C2780482068 @default.
• W2947843536 hasConcept C2908647359 @default.
• W2947843536 hasConcept C29456083 @default.
• W2947843536 hasConcept C512399662 @default.
• W2947843536 hasConcept C530470458 @default.
• W2947843536 hasConcept C71924100 @default.
• W2947843536 hasConcept C72563966 @default.
• W2947843536 hasConcept C99454951 @default.
• W2947843536 hasConceptScore W2947843536C121608353 @default.
• W2947843536 hasConceptScore W2947843536C126322002 @default.
• W2947843536 hasConceptScore W2947843536C143998085 @default.
• W2947843536 hasConceptScore W2947843536C167135981 @default.
• W2947843536 hasConceptScore W2947843536C2775930923 @default.
• W2947843536 hasConceptScore W2947843536C2777176818 @default.
• W2947843536 hasConceptScore W2947843536C2778812593 @default.
• W2947843536 hasConceptScore W2947843536C2779744173 @default.
• W2947843536 hasConceptScore W2947843536C2780482068 @default.
• W2947843536 hasConceptScore W2947843536C2908647359 @default.
• W2947843536 hasConceptScore W2947843536C29456083 @default.
• W2947843536 hasConceptScore W2947843536C512399662 @default.
• W2947843536 hasConceptScore W2947843536C530470458 @default.
• W2947843536 hasConceptScore W2947843536C71924100 @default.
• W2947843536 hasConceptScore W2947843536C72563966 @default.
• W2947843536 hasConceptScore W2947843536C99454951 @default.
• W2947843536 hasIssue "15_suppl" @default.
• W2947843536 hasLocation W29478435361 @default.
• W2947843536 hasOpenAccess W2947843536 @default.
• W2947843536 hasPrimaryLocation W29478435361 @default.
• W2947843536 hasRelatedWork W2740803632 @default.
• W2947843536 hasRelatedWork W2751810360 @default.
• W2947843536 hasRelatedWork W2896846857 @default.
• W2947843536 hasRelatedWork W2915354113 @default.
• W2947843536 hasRelatedWork W3136162983 @default.
• W2947843536 hasRelatedWork W3203690439 @default.
• W2947843536 hasRelatedWork W4226356606 @default.
• W2947843536 hasRelatedWork W4243951155 @default.
• W2947843536 hasRelatedWork W4248732404 @default.
• W2947843536 hasRelatedWork W4282924254 @default.
• W2947843536 hasVolume "37" @default.
• W2947843536 isParatext "false" @default.
• W2947843536 isRetracted "false" @default.
• W2947843536 magId "2947843536" @default.
• W2947843536 workType "article" @default.